oncodaily - Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared on LinkedIn by Sarwish Rafiq, Assistant Professor at the Emory University School of Medicine and […]
AI Summary: Researchers published a novel CAR T‑cell approach exploiting the VIP–VIPR pathway that reprograms cells for superior antitumor activity in preclinical models. The Winship team’s paper reports enhanced tumor killing and durability in laboratory studies, flagging a promising route to improve CAR T efficacy in solid tumors — still very early, but intriguing.
CAR‑T depletes mutant calreticulin cells, offering myelofibrosis hope / 20 days
Dendritic cells build tumour immune hubs sustaining anti-tumour responses / 5 days
Mass spectrometry platform could cut drug discovery to hours / 4 wks
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 4 months
Ten‑year follow‑up shows durable remissions with CD19 CAR‑T therapy / 28 days
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 2 months
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 4 hrs
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.